Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J, Cao Y, Zhang Q, Liu W, Zhou X, Ming X, Meng F, Zhang Y, Li C, Huang L, Wei J, Zheng M, Zhang S, Zhang T, Zhu X, Wang N, Wang J, Wang G, Zhou J, Liu B, Xiao Y.
Wu J, et al. Among authors: liu b, liu w.
Front Immunol. 2022 May 20;13:879983. doi: 10.3389/fimmu.2022.879983. eCollection 2022.
Front Immunol. 2022.
PMID: 35669773
Free PMC article.